September 21, 2026
Research
DHA and Dry Eye: What the Trials Actually Found
October 6, 2026 · 8 min read
A trial that embarrassed the entire category
Five hundred and thirty-five people with moderate-to-severe dry eye disease took capsules every day for a year. Half got 3,000 mg of fish-derived EPA and DHA. Half got olive oil.
Both groups improved by around 13 points on the Ocular Surface Disease Index, the standard 12-question symptom scale. The gap between them was 1.9 points — not statistically significant, and well under the 10-point shift doctors treat as meaningful to a patient.
That is the DREAM trial: 27 US eye clinics, published in the New England Journal of Medicine in 2018, and still the largest and longest randomised trial anyone has run on omega-3 and dry eye. It found no advantage over an edible placebo on symptoms, and none on any of four physical signs either — tear break-up time, Schirmer's test wetting, or staining of the eye's surface.
DREAM: 535 Patients, 12 Months, No Separation From Placebo
Active supplement delivered 2,000 mg EPA and 1,000 mg DHA daily. Placebo was refined olive oil. Mean symptom change was -13.9 points on active versus -12.5 on placebo — a difference of 1.9 points that did not reach significance. None of the four measured signs of dry eye disease separated between groups either.
Source: Asbell et al., New England Journal of Medicine, 2018 (n=535).
Dry eye disease affects roughly one in seven US adults and costs the economy more than $55 billion a year in care and lost output. Women past menopause and anyone logging long hours at a screen carry a disproportionate share of that burden — which is exactly why the omega-3 aisle markets so hard at this age group. A result this size, from a trial this careful, deserves more attention than it gets in most of that marketing.
The pooled trial data tells a more complicated story
DREAM is one trial. The Cochrane Collaboration's 2019 review of the entire field reached a split verdict rather than a flat no.
On symptoms people reported themselves, the evidence was weak: four trials in 677 people found little to no difference against placebo, rated low-certainty. On physical signs, it was stronger. Omega-3 probably increased tear production and probably improved tear break-up time — both rated moderate-certainty, Cochrane's second-highest grade.
A larger 2023 meta-analysis pooling 19 trials and 4,246 patients found a clearer benefit across the board, symptoms included.
Effect size here is a standardised mean difference, a way of comparing results measured on different scales. Above 0.8 counts as a large effect by convention; this review found two of five outcomes above that line. The gap with Cochrane's more cautious reading comes down to which trials were pooled and how strictly they were screened for bias. Treat the figures above as the optimistic end of a genuine range, not a settled number.
What DHA is actually doing to your eyes
Your tear film has three layers, and the outermost is oil, produced by meibomian glands lining your eyelids. When those glands clog or the oil thickens, the layer breaks down and tears evaporate faster than they should. That is meibomian gland dysfunction, and it drives a large share of dry eye cases.
DHA is a long, loosely packed fatty acid. Built into meibum, it is thought to lower the oil's melting point, so it flows more easily at eyelid temperature and spreads more evenly with each blink. That is the specific mechanistic case for DHA, distinct from omega-3's general anti-inflammatory reputation.
Meibomian gland dysfunction is thought to be the single most common cause of dry eye, which is why recent trials increasingly target it by name rather than lumping all dry eye together. A standard fish oil capsule rarely supplies enough DHA to test that mechanism at the dose the positive trials actually used.
The dose that moved the needle
A 2021 South Korean trial tested that mechanism directly. Fifty adults with dry eye and confirmed meibomian gland dysfunction took either a high-DHA supplement or an olive oil placebo for eight weeks.
The active capsules delivered 600 mg of EPA and 1,640 mg of DHA daily — more than six times the dose that earns DHA's GB-authorised vision claim. Tear break-up time rose from 4.1 to 6.0 seconds in the treatment group, against 3.8 to 5.1 seconds on placebo. The meibomian gland dysfunction score, where lower is better, fell from 8.7 to 7.2 on treatment; the placebo group barely moved, from 8.6 to 8.1.
High-Dose DHA and Meibomian Gland Dysfunction
Fifty patients, eight weeks, 1,640 mg DHA plus 600 mg EPA daily against olive oil placebo. Tear break-up time and the meibomian gland dysfunction score improved significantly more on active treatment. Most of the gain appeared between week four and week eight, not immediately.
Source: Jo et al., International Journal of Ophthalmology, 2021 (n=50).
Fifty people is a small trial, and eight weeks is short next to DREAM's twelve months. But the dose gap between what worked here and what DREAM used — more DHA, markedly less EPA — is the detail most coverage skips.
EPA, not DHA, might be the fraction that matters
Here is the complication for a DHA-led product. In the 2023 meta-analysis above, a meta-regression across all 19 trials found that the proportion of EPA in a formula, not the total dose and not the DHA content, correlated most strongly with symptom improvement.
That does not mean DHA does nothing — the Korean trial used a DHA-dominant formula and still beat placebo. It means the strongest statistical case for this particular outcome points toward EPA, which most DHA-specific marketing does not mention. We've covered where the two fatty acids genuinely diverge in DHA vs EPA: what each one does in your body, and dry eye is one more entry on that list.
Omega-3 does not stop dry eye from starting
Everything so far concerns people who already have dry eye. Prevention is a separate question, and the data on it is unusually decisive.
The VITAL trial followed 23,523 healthy US adults for a median of 5.3 years, randomising half to 1 g of marine omega-3 daily and half to placebo. By the end, the two groups showed no difference in how many people went on to develop dry eye, and no difference in severe symptom rates either.
VITAL: 23,523 Healthy Adults, 5.3 Years, No Preventive Effect
Daily 1 g marine omega-3 versus placebo in adults free of dry eye at baseline. Over a median 5.3-year follow-up, omega-3 did not reduce the incidence of diagnosed dry eye or severe dry eye symptoms.
Source: Buring et al., JAMA Ophthalmology, 2022 (n=23,523).
Twenty-three thousand people followed for five years is about as decisive as nutrition trials get. If your eyes are currently comfortable, there is no evidence that a daily omega-3 capsule keeps them that way.
What to actually do if your eyes are dry
NHS guidance treats mild dry eye as self-care territory first. Preservative-free artificial tears, used as needed, are the best-evidenced starting point, and any treatment is meant to run for four to six weeks before you judge whether it is working.
If you want to add omega-3 on top of artificial tears, match the dose to the evidence rather than to whatever a single capsule happens to contain. The trial that found a clear benefit used 1,640 mg of DHA plus 600 mg of EPA for eight weeks. DREAM used more total omega-3 — 3,000 mg — but a different EPA-to-DHA ratio, and found nothing over twelve months. Dose and ratio both appear to matter, and neither is settled.
A diagnosed cause changes the odds. Omega-3 looks more promising in people with confirmed meibomian gland dysfunction than in dry eye generally, and it looks like nothing at all as a way to stop dry eye from starting. Get a proper diagnosis before you decide a supplement is the fix.
Screen use plays its own, largely separate role; we've covered the blink-rate evidence in screen fatigue and omega-3. And if dose is the sticking point, how much DHA you actually need per day breaks down the gap between label claims and trial doses more broadly.
See an optometrist if symptoms persist past six weeks of self-care, if you wear contact lenses, or if staining or persistent redness shows up on examination. None of that resolves on its own from a capsule, whatever the dose.
Gastrointestinal upset is the most commonly reported side effect at these higher doses, and anyone on anticoagulants should ask a pharmacist before adding several grams of fish oil a day. The honest summary: oily fish twice a week, properly diagnosed meibomian gland dysfunction treated with real doses, and artificial tears first. A single fish oil capsule marketed at dry eye, on its own, is not what moved the needle in any trial above.
References
- Asbell PA, Maguire MG, Pistilli M, Ying GS, Szczotka-Flynn LB, Hardten DR, Lin MC, Shtein RM; DREAM Study Research Group (2018). "n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease." New England Journal of Medicine, 378(18), 1681-1690. DOI: 10.1056/NEJMoa1709691.
- Wang WX, Ko ML (2023). "Efficacy of Omega-3 Intake in Managing Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Journal of Clinical Medicine, 12(22), 7026. DOI: 10.3390/jcm12227026.
- Downie LE, Ng SM, Lindsley KB, Akpek EK (2019). "Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease." Cochrane Database of Systematic Reviews, Issue 12, CD011016. DOI: 10.1002/14651858.CD011016.pub2.
- Buring JE, Lee IM, Bubes V, Friedenberg G, Dushkes R, Smith D, Schaumberg DA; VITAL Research Group (2022). "Efficacy of Marine Omega-3 Fatty Acid Supplementation vs Placebo in Reducing Incidence of Dry Eye Disease in Healthy US Adults: A Randomized Clinical Trial." JAMA Ophthalmology, 140(7), 707-714. DOI: 10.1001/jamaophthalmol.2022.1818.
- Jo YJ, et al. (2021). "Effects of dietary high dose DHA omega-3 supplement in dry eye with meibomian gland dysfunction." International Journal of Ophthalmology, 14(11), 1703-1709. DOI: 10.18240/ijo.2021.11.08.
- Great Britain nutrition and health claims register (retained Regulation (EC) No 1924/2006; Commission Regulation (EU) No 432/2012). Authorised claim: DHA contributes to the maintenance of normal vision at a daily intake of 250 mg.
Continue Reading
August 18, 2026